The 39th Annual New Treatments in Chronic Liver Disease 2025 is a course dedicated to new medications and therapies in the treatment of the following:
- Current knowledge of NAFLD and non-alcoholic steatohepatitis and the use of new agents and approaches to treatment of the conditions
- The details of the AASLD guidelines for treatment of HCV using DAAs in IFN-free regimens
- Therapies for HCV including NS5A, protease and polymerase inhibitors
- The algorithm for a therapeutic approach to treatment of HBV using anti-virals
- Current options of therapy for hepatocellular carcinoma to determine the best approach for your patients
- The skills and management required for transplant hepatology
- The diagnosis and treatment of PBC and PSC
- Future treatment paradigms for HCV direct-acting antiviral drug
- The issues complicating drug treatment in decompensated cirrhosis, hepatic encephalopathy and hyponatremia
- Treatment options discussed for patients with ESLD due to alcohol who have complicating factors such as HCV, NASH or inherited genetic disorder
- The management of complications beta-blocker therapy in ESLD
Who should Attend
Hepatologists , Physician Assistants , Residents/Fellows , Nurses , Nurse Practitioners , Gastroenterologists , Infectious Disease Specialists and Others desiring an update in these specialty areas .
